0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Chronic Immune Stimulation and Subsequent Waldenström Macroglobulinemia FREE

Jill Koshiol, PhD; Gloria Gridley, MS; Eric A. Engels, MD, MPH; Mary L. McMaster, MD; Ola Landgren, MD, PhD
[+] Author Affiliations

Author Affiliations: Cancer Prevention Fellowship Program, Office of Preventive Oncology (Dr Koshiol), and Division of Cancer Epidemiology and Genetics (Drs Koshiol, Engels, McMaster, and Landgren and Ms Gridley), National Cancer Institute, Bethesda, Maryland.


Arch Intern Med. 2008;168(17):1903-1909. doi:10.1001/archinternmed.2008.4.
Text Size: A A A
Published online

Background  Certain autoimmune and infectious conditions are associated with increased risks of subtypes of non-Hodgkin lymphoma. A few previous studies suggest that chronic inflammation may particularly elevate risk of the distinct non-Hodgkin lymphoma subtype Waldenström macroglobulinemia (WM).

Methods  We assessed WM risk in relation to a variety of chronic immune stimulatory conditions in 4 million US veterans. We identified 361 patients with WM with up to 27 years of follow-up. Using time-dependent Poisson regression, we estimated rate ratios (RRs) and 95% confidence intervals (CIs) for WM risk in relation to history of autoimmune diseases that typically have autoantibodies (with systemic or organ involvement) or do not have autoantibodies, infections, and allergies. All the models were adjusted for attained age, calendar year, race, number of hospital visits, and latency between study entry and exit.

Results  The age-standardized incidence of WM was 0.34 per 100 000 person-years. Risk of WM was elevated in individuals with any previous autoimmune condition (RR, 2.23; 95% CI, 1.68-2.97), autoantibodies with systemic involvement (2.50; 1.55-4.02), or autoantibodies with organ involvement (2.30; 1.57-3.37). Risks of WM were also increased with hepatitis (RR, 3.39; 95% CI, 1.38-8.30), human immunodeficiency virus (12.05; 2.83-51.46), and rickettsiosis (3.35; 1.38-8.14).

Conclusions  In the largest investigation of WM risk factors to date, we found a 2- to 3-fold elevated risk of WM in persons with a personal history of autoimmune diseases with autoantibodies and notably elevated risks associated with hepatitis, human immunodeficiency virus, and rickettsiosis. These findings provide novel insights into the still unknown etiology of WM.

Figures in this Article

Waldenström macroglobulinemia (WM) is a distinct B-cell subtype of non-Hodgkin lymphoma (NHL) characterized by lymphoplasmacytic infiltration of the bone marrow and a monoclonal IgM protein.1,2 Patients often present initially with nonspecific symptoms. The most common symptoms are fatigue and malaise attributable to anemia. Other findings may include hepatomegaly (20% of patients), splenomegaly (15%), lymphadenopathy (15%-20%), hyperviscosity (15%), and peripheral neuropathy (20%).3 Typically, clinical symptoms are attributable to the extent of tumor infiltration and to elevated monoclonal IgM levels.4

Based on data from the Surveillance, Epidemiology, and End Results (SEER) Program, WM is a rare malignancy, affecting 3 to 4 of every 1 million people in the United States annually.5,6 In the SEER Program, white individuals seem to have a higher incidence rate than black individuals, and risk increases with age.5,6 Individuals with a history of the precursor condition monoclonal gammopathy of undetermined significance (MGUS) of IgM class have an elevated risk of WM, other types of lymphomas, or related disorders.7 Based on data from the Mayo Clinic, risk of progression from MGUS to WM is associated with the initial monoclonal protein concentration.8 Reports of multiply affected families from case series and smaller single-center studies suggest that genetic factors may contribute.916 Although the first genomewide linkage analysis17 based on 11 high-risk WM families was recently conducted, the genetic determinants of WM susceptibility remain to be defined.

Small case studies18,19 of patients with WM have found immunoglobulin gene mutations that suggest a role for repeated antigenic stimulation in the etiology of WM. Indeed, a recent study20 on hepatitis C virus (HCV) infection in US military veterans found an almost 3-fold increased risk of WM in HCV-infected compared with uninfected individuals. The study also found a slight increase in MGUS incidence, which may suggest that HCV infection drives progression from MGUS to WM through chronic immune stimulation.20 In addition, the incidence of lymphoma increases notably with age for most subtypes.6 This pattern suggests that chronic inflammation, which is associated with older age and cancer,21,22 may be a potential risk factor.6 Thus, it may be important to evaluate a broad range of infectious diseases that could increase the risk of WM through chronic inflammation and immune stimulation. Finally, autoimmune disease is another important source of chronic immune stimulation. Although autoimmune disease is associated with lymphomas overall,2325 the association between autoimmune disease and WM has not been well examined. To our knowledge, only 1 previous small case-control study26 of 65 cases has evaluated WM risk in relation to autoimmunity. Analysis of all conditions combined found no association with WM risk. However, because of the restricted sample size, autoimmune conditions could not be analyzed individually.

To address these gaps and further explore underlying pathologic mechanisms, we conducted a study of WM risk in a cohort of 4 million adult male military veterans admitted to US Veterans Affairs (VA) hospitals. This study is the largest to date to evaluate a wide range of chronic immune stimulatory conditions in relation to WM risk.

PATIENTS, OUTCOMES, AND EXPOSURES

The study population came from a pool of approximately 30 million US veterans entitled to VA hospital admission during the study period.27 The cohort was identified from the VA database of inpatient records from 142 US VA hospitals between July 1, 1969, and September 30, 1996. Eligible patients included male white or black US veterans 18 years or older with at least 1 hospitalization during the study period. They also had to be cancer free during the first year of follow-up and had to survive at least 1 year after the initial visit. Other ethnic/racial groups and females were excluded given their limited representation. The National Institutes of Health Office of Human Subjects Research granted exemption from institutional review board review and waived informed consent because the study was restricted to existing data that were stripped of personal identifiers.

The eighth and ninth revisions of the International Classification of Diseases (ICD-8-A and ICD-9-CM) were used to code diagnoses for WM (coded 275.5 and 273.3, respectively) and for specific autoimmune, infectious, and allergic conditions. In accord with previous studies,23 autoimmune conditions were categorized as those that generally have detectable autoantibodies and those that do not. Bacterial, viral, parasitic, and total infections were analyzed as combined categories. Results for individual immune stimulatory conditions are presented only if 3 or more people with the condition developed WM.

STATISTICAL ANALYSIS

For all the patients, person-time began 1 year after the index hospital discharge and continued until diagnosis of the first malignancy (WM), death, or the end of the observation period (September 30, 1996), whichever came first. Dates of death were ascertained from record linkage to Social Security Administration mortality files. The length of time from diagnosis of a chronic immune stimulatory condition (autoimmunity, infections, and allergies) to the development of WM was calculated by subtracting the date of the first hospital discharge diagnosis for an immune stimulatory condition from the date of the first hospital discharge diagnosis of WM.

Incidence rates for WM were age standardized to the 2000 US population distribution (http://factfinder.census.gov/). Rate ratios (RRs) and 95% confidence intervals (CIs) for the association between chronic immune stimulatory conditions and risk of WM were calculated using time-dependent Poisson regression28 (AMFIT module in Epicure version 1.4) adjusting for attained age (<40, 40-49, 50-59, 60-69, 70-79, ≥80 years), calendar year (1969-1974, 1975-1979, 1980-1984, 1985-1989, and 1990-1996), race (black vs white), number of hospital visits (1-2, 3-4, ≥5 times), and latency between study entry and exit (2-3, 4-5, 6-9, 10-14, ≥15 years). All P values and CIs were 2-sided.

To evaluate the potential for reverse causality (ie, undetected WM causing the immune-related conditions), models were stratified by latency (time in the cohort) of 5 years or less and more than 5 years for conditions with more than 10 exposed cases and at least 3 in each stratum (≤5 and >5 years). Modification of the RRs for these conditions and WM by latency was formally evaluated using the likelihood ratio test (LRT) for multiplicative interaction. For conditions of particular interest with fewer than 10 exposed cases, we described the time between exposure and WM for the exposed cases. We evaluated models stratified by median calendar time (before 1985 and 1985 and later) using the strategy described previously herein (>10 exposed cases, >2 in each stratum) to assess whether the estimates were stable across time, and the results were very similar before and after 1985. Because the incidence of WM varies by race,5,6 we also stratified the models by race.

There were 361 patients with WM in this cohort of hospitalized veterans with mean follow-up of 12 years (Table 1). The age-standardized incidence rate for WM was 0.34 per 100 000 person-years. There was some evidence that the rate was lower in black patients (0.26 per 100 000 person-years) than in white patients (0.37 per 100 000 person-years), corresponding to an RR of 0.74 (95% CI, 0.54-1.01).

Table Graphic Jump LocationTable 1. Characteristics of the Study Cohort (US Veterans Affairs): White and Black Male Veterans With at Least 1 Hospital Admission Between July 1, 1969, and September 30, 1996, and Followed Up for More Than 1 Year

Autoimmune disease was associated with a 2- to 3-fold increase in risk of subsequent WM (Table 2). The RR for autoimmune disease overall was 2.23 (95% CI, 1.68-2.97). Much of this increase seemed to be due to autoimmune diseases that generally have detectable autoantibodies (RR, 2.50; 95% CI, 1.55-4.02 for systemic involvement and 2.30; 1.57-3.37 for organ involvement). However, Crohn disease, which does not have detectable autoantibodies, seemed to be very strongly associated with WM (RR, 6.68; 95% CI, 2.76-16.20), although the estimate was imprecise because there were only 5 exposed cases. The relation between WM and immune thrombocytopenic purpura (ITP) was also strong (RR, 6.88; 95% CI, 2.84-16.64), and Sjögren syndrome produced the most prominent association with WM (13.59; 4.36-42.41), although it was based on small numbers.

Table Graphic Jump LocationTable 2. Risk of Waldenström Macroglobulinemia (WM) in Relation to Previous Personal History of Selected Autoimmune Diseasesa

The RRs for WM associated with autoimmune conditions tended to be higher for latency of 5 years or less compared with more than 5 years (Table 2). For example, the RR for total autoimmune disease was 4.01 (95% CI, 2.06-6.18) for 5 years or less vs 1.61 (1.11-2.34) for more than 5 years (LRT P = .002). Numbers were too small to evaluate Sjögren syndrome, ITP, and Crohn disease in stratified latency models, but the mean time between exposure and WM was fairly short for Sjögren syndrome and ITP: 2.2 years (median, 0.9 years; range, 0.3-5.4 years) and 2.6 years (median, 2.1 years; range, 0.8-4.2 years), respectively. However, the mean time between exposure and WM was 9.2 years for Crohn disease (median, 9.9 years; range, 0.7-18.1 years).

The RR for autoimmune disease and WM in black patients was lower than that in white patients, but there was no indication of multiplicative interaction between race and autoimmune disease (LRT P = .41) (Figure). Only 4 black patients had both autoimmune disease and WM.

Place holder to copy figure label and caption
Figure.

Forest plots of the rate ratios (RRs) for specific conditions and subsequent Waldenström macroglobulinemia in black and white patients. The likelihood ratio test (LRT) provides a formal evaluation of the difference in RRs by race. Error bars indicate confidence intervals. All analyses were adjusted for age, calendar time, race, latency, and number of hospital visits.

Graphic Jump Location

Infectious diseases generally did not seem to be associated with increased risk of WM, with a few exceptions: hepatitis (RR, 3.39; 95% CI, 1.38-8.30), human immunodeficiency virus (HIV) (12.05; 2.83-51.46), and rickettsiosis (3.35; 1.38-8.14) (Table 3). There was also some evidence of a positive association between herpes zoster and WM (RR, 2.30; 95% CI, 0.95-5.58). There were no apparent associations with grouped bacterial (RR, 1.13; 95% CI, 0.87-1.51), viral (1.39; 0.87-2.22), or parasitic (1.24; 0.77-2.02) infections or with infections overall (0.92; CI, 0.74-1.15).

Table Graphic Jump LocationTable 3. Risk of Waldenström Macroglobulinemia (WM) in Relation to Previous Personal History of Selected Infectious Diseasesa

In contrast to the latency pattern for autoimmune conditions, the RRs for infectious conditions were fairly similar for latency of 5 years or less compared with more than 5 years (Table 3). The RRs seemed to be somewhat elevated in the 5 years or less group for chronic sinusitis and tuberculosis, although there was little evidence of multiplicative interaction (LRT P = .47 and .20, respectively). The mean time between exposure and WM was 3.4 years for hepatitis (median, 2.9 years; range, 0.1-7.9 years), 9.8 years for gingivitis and periodontitis (median, 6.8 years; range, 0.1-24.1 years), 1.6 years for HIV (median, 1.1 years; range, 1.1-2.7 years), 4.2 years for rickettsiosis (median, 1.4 years; range, 0.7-15.4 years), and 4.7 years for herpes zoster (median, 4.7 years; range, 1.5-7.4 years).

For infectious diseases, the RRs from models restricted to black individuals were higher than those from models restricted to white individuals (Figure). There was some evidence of multiplicative interaction between race and parasitic infections (LRT P = .02), pneumonia (LRT P = .06), and gingivitis and periodontitis (LRT P = .08), although the estimates were imprecise. Of the infections included in the Figure, black patients had a higher percentage of the infectious conditions than did white patients (Table 4). However, the percentage of infections was generally only 1% to 2% higher in black vs white non-WM patients but approximately 3% to 14% higher in black vs white patients with WM (Table 4).

Table Graphic Jump LocationTable 4. Selected Infectious Conditions in Black and White Patients With and Without Waldenström Macroglobulinemia (WM)

Twenty-two patients with WM had allergies, including 10 with asthma, 5 with dermatitis, and 2 with urticaria. Overall, allergy was not associated with WM (RR, 1.03; 95% CI, 0.67-1.60). The RRs were 0.53 (95% CI, 0.22-1.29) for dermatitis and 1.28 (0.68-2.40) for asthma. The RRs for allergy by latency were the same (LRT P > .50). The data were too sparse to evaluate allergies by race.

In a subanalysis, we found that 19 of the 361 patients with WM (5%) had a previously reported MGUS diagnosis. There is likely a very high degree of underascertainment of MGUS in the database because MGUS is generally an asymptomatic condition. Also, this patient population was never systematically screened for MGUS.

In the first large, systematic assessment of immune-related risk factors in relation to risk of WM, we found that autoimmune conditions, such as rheumatoid arthritis, Sjögren syndrome, and Crohn disease, were positively associated with WM, consistent with previous studies of NHL overall.24,25 Infections generally did not seem to be associated with WM risk, with a few exceptions, and allergies were not associated, although power was limited.

To our knowledge, the only previous study of chronic immune stimulatory conditions and WM is a case-control study26 of 65 patients with WM and 213 hospital controls that could not evaluate specific individual immune-related conditions owing to the small number of cases. We found that the risk of WM was elevated 2- to 3-fold for autoimmune disorders with detectable autoantibodies but not for those without detectable autoantibodies. Thus, associations with WM may vary by category of autoimmune disease. We also found that specific autoimmune diseases—Sjögren syndrome, ITP, and Crohn disease—were the most strongly associated with WM risk, although these estimates were imprecise.

Based on small numbers, we found a prominent 14-fold risk of WM in persons with Sjögren syndrome. Previous studies25 have consistently shown an increased risk of B-cell NHL in patients with Sjögren syndrome. Anatomically, these lymphomas are typically of indolent NHL subtypes, often of the mucosa-associated lymphoid tissue type.25 Recently, there has been some evidence that patients with Sjögren syndrome might also have an elevated risk of other lymphomas, such as diffuse large B-cell and anaplastic large T-cell lymphomas.29 To our knowledge, this study is the first to report an association between Sjögren syndrome and WM.

The present study and the previous study by Linet et al26 found no association between infectious diseases overall and WM. However, in the present study, we evaluated specific individual infections and found that some (eg, hepatitis, HIV, and rickettsiosis) were associated with an increased risk of WM. This study expands on the previous analysis of HCV and risk of WM by demonstrating that hepatitis B was also associated with WM, supporting the hypothesis that infection with hepatitis viruses may cause chronic immune stimulation, leading to the development of WM.20 To our knowledge, we are the first to find that HIV was associated with increased WM risk. This observation is consistent with the large body of literature that shows that HIV is associated with highly elevated risks of B-cell NHLs.30 The association with rickettsiosis is unexpected, especially because rickettsiosis is rare. Patients with rickettsial pathogens can show symptoms of lymphadenopathy,31 which may indicate activation of the immune system, leading to chronic immune stimulation. Alternatively, hospitalization due to rickettsiosis may suggest the presence of an underlying immune deficit, leading to the diagnosis of WM.

This study is also the first to evaluate the effect of race on the association between chronic immune stimulatory conditions and WM. The risk of WM associated with infections was consistently higher in black patients than in white patients, which is surprising given that the incidence of WM is lower in black patients than in white patients. If true, some other risk factor must be driving the risk in whites. It is possible that the pattern of elevated RRs for infections in black patients might reflect racial differences in immune responses to infectious agents.3234 However, given the number of exposures evaluated, these findings have to be interpreted with caution because they could be due to chance.

To evaluate the possibility that WM may have been present before diagnosis of the chronic immune stimulatory conditions and may have actually caused these conditions (ie, reverse causality), we stratified by latency of 5 years or less and more than 5 years. For autoimmune disease, the increase in the risk of WM was evident mainly in the 5 years before WM, and some conditions were diagnosed less than 1 year before WM diagnosis. These patterns suggest that in some patients, the autoimmune disease could be a manifestation of underlying undetected WM, especially considering that WM often has a long latency period.35 In particular, ITP is a recognized complication of WM.36,37 However, because the risk of WM in patients with autoimmune diseases remained elevated after 5 years, similar to the results of a population-based study24 of NHL in Denmark and Sweden, we believe that these findings are not entirely due to undetected WM. Clinical workup for the suspicion of an autoimmune disease typically includes a complete blood cell count and may include protein electrophoresis, which should lead to WM diagnosis at or shortly after onset of the autoimmune disease. Although some autoimmune diseases did have a relatively short median time to WM diagnosis (eg, ITP and Sjögren syndrome), others did not (eg, Crohn disease). We do not have access to individual detailed clinical data that would allow us to evaluate the role of previous diagnosis of MGUS or undetected early-stage WM directly. Thus, future epidemiologic studies must verify these findings through medical record validation of clinical, diagnostic, prognostic, and treatment data.

For infections, the similarity in RRs for latency of 5 years or less and more than 5 years argues against reverse causality for this group of chronic immune stimulatory conditions. Although the data for many individual infectious conditions were too sparse to stratify by latency, the relatively short medians for some conditions suggest that interpretation requires caution. For example, the median time to WM diagnosis was approximately 1 year for rickettsiosis and HIV, which could reflect detection bias (ie, rickettsiosis or HIV detected owing to workup for WM). On the other hand, the short time to WM diagnosis for HIV may reflect the fact that a separate ICD code for HIV was not added until 1987, resulting in a shorter amount of time available for the diagnosis of HIV and WM.

Chronic immune stimulatory conditions may contribute to lymphomagenesis through persistent activation of lymphocytes, leading to a reduced antigen response, increased mutation rates, and a downregulated T-cell response, potentially disrupting the immune response to pathogens and malignant cells.38,39 Although further studies are needed, the present findings support the hypothesis that chronic immune stimulation may contribute to the development of WM.

This study has some limitations. First, these results may not be generalizable to the US population. It is, however, encouraging that the age-adjusted rates of WM in this cohort are similar to those found for males in the SEER Program overall (0.35 per 100 000 person-years in the present study vs 0.35 per 100 000 person-years in the SEER Program),5 in white patients (0.37 per 100 000 person-years in the present study vs 0.36-0.56 per 100 000 person-years in the SEER Program),5,6 and in black patients (0.26 per 100 000 person-years in the present study vs 0.17-0.25 per 100 000 in the SEER Program).5,6 Because the data are based on hospital claims, it is possible that some conditions might have developed before the patient entered the VA system. The definition of WM is limited by the fact that the ICD-8-A code for WM was not entirely specific but also included macroglobulinemia (ie, MGUS type IgM); by the lack of review for WM cases and immune-mediated conditions because demographic, clinical, treatment, laboratory, and biomarker information were unavailable; and by revisions in the definition of WM with time (eg, it was not reportable as a malignancy in the United States until 198840). However, as mentioned previously herein, the risk estimates were similar when stratified by calendar period, suggesting that these limitations have not introduced any major bias. Because we did not have treatment data, we could not evaluate potential confounding by immunosuppressive therapy, which is used to treat severe autoimmune disease and is also associated with the development of lymphoma.41 Because the clinical workup of immune-related diseases might include protein electrophoresis, it is possible that some of the present results for autoimmune conditions are overestimated owing to surveillance bias: patients with autoimmune disease may be more likely to have WM diagnosed than patients without autoimmune disease. Also, one has to keep in mind that all patients (with and without WM) in this cohort were hospitalized, which presumably led to more clinical workup than in the general population. For this reason, we did not use external controls but instead applied a cohort study design, allowing us to use internal controls. Although this cohort included more than 4 million patients, the rarity of WM and of some of the chronic immune stimulatory conditions evaluated limited analyses and led to imprecision in some estimates. Multiple comparisons may result in chance findings. Furthermore, exposures that have been discovered recently (eg, HCV in 1989 and HIV in 1983) and less severe autoimmune and infectious conditions that do not lead to hospitalization may not be well represented.

The strengths of this study include its extensive follow-up in a patient population with access to standardized medical care that does not depend on socioeconomic status. Furthermore, there is no recall bias because the exposure information is obtained from medical records. Because of the size of this population, we could evaluate the incidence of WM in black patients and provide the first analysis of risk factors for WM in black patients.

In summary, we found that WM is associated with autoimmune diseases, especially those with detectable autoantibodies, in the largest study of chronic immune stimulatory conditions and WM to date. Patients with specific infectious diseases, such as hepatitis, HIV, and rickettsiosis, also seemed to be at increased risk for WM. These results suggest that chronic immune stimulation plays an important role in the etiology and pathogenesis of WM. Better characterization of the mechanisms that mediate clonal proliferation and survival will ultimately enhance our understanding of the pathogenesis of WM, provide clues to etiology, and allow identification of novel molecular targets.

Correspondence: Jill Koshiol, PhD, Genetic Epidemiology Branch, National Cancer Institute, 6120 Executive Blvd, EPS 7003, MSC 7236, Bethesda, MD 20892-7236 (koshiolj@mail.nih.gov).

Accepted for Publication: March 30, 2008.

Author Contributions: Dr Koshiol had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Landgren. Acquisition of data: Gridley. Analysis and interpretation of data: Koshiol, Gridley, Engels, McMaster, and Landgren. Drafting of the manuscript: Koshiol and Landgren. Critical revision of the manuscript for important intellectual content: Koshiol, Gridley, Engels, McMaster, and Landgren. Statistical analysis: Koshiol, Gridley, and Engels. Obtained funding: Gridley. Administrative, technical, and material support: Koshiol, McMaster, and Landgren. Study supervision: Landgren.

Financial Disclosure: None reported.

Funding/Support: This research was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health.

Additional Contributions: The Medical Administration Service of the Veterans Health Services and Research Administration provided the data on which this study is based; David Campbell, BA, and Eric Boyd, BS, Information Management Services, assisted with data preparation; and David Check, BS, assisted with the creation of the Figure.

Berger  FIsaacson  PGPiris  MA  et al.  Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Jaffe  ESHarris  NLStein  HVardiman  JW World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press2001;132- 134
Owen  RGTreon  SPAl Katib  A  et al.  Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003;30 (2) 110- 115
PubMed Link to Article
Fonseca  RHayman  S Waldenström macroglobulinaemia. Br J Haematol 2007;138 (6) 700- 720
PubMed Link to Article
Vijay  AGertz  MA Waldenström macroglobulinemia. Blood 2007;109 (12) 5096- 5103
PubMed Link to Article
Groves  FDTravis  LBDevesa  SSRies  LAFraumeni  JF  Jr Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998;82 (6) 1078- 1081
PubMed Link to Article
Morton  LMWang  SSDevesa  SSHartge  PWeisenburger  DDLinet  MS Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107 (1) 265- 276
PubMed Link to Article
Kyle  RATherneau  TMRajkumar  SV  et al.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102 (10) 3759- 3764
PubMed Link to Article
Kyle  RARajkumar  SVTherneau  TMLarson  DRPlevak  MFMelton  LJ  III Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance. Clin Lymphoma 2005;5 (4) 257- 260
PubMed Link to Article
Blattner  WAGarber  JEMann  DL  et al.  Waldenström's macroglobulinemia and autoimmune disease in a family. Ann Intern Med 1980;93 (6) 830- 832
PubMed Link to Article
Brown  AKElves  MWGunson  HHPell-Ilderton  R Waldenströms macroglobulinaemia: a family study. Acta Haematol 1967;38 (3) 184- 192
PubMed Link to Article
Elves  MWBrown  AK Cytogenetic studies in a family with Waldenström's macroglobulinaemia. J Med Genet 1968;5 (2) 118- 122
PubMed Link to Article
Gétaz  EPStaples  WG Familial Waldenström's macroglobulinaemia: a case report. S Afr Med J 1977;51 (24) 891- 892
PubMed
McMaster  MLGiambarresi  TVasquez  LGoldstein  AMTucker  MA Cytogenetics of familial Waldenstrom's macroglobulinemia: in pursuit of an understanding of genetic predisposition. Clin Lymphoma 2005;5 (4) 230- 234
PubMed Link to Article
Ogmundsdóttir  HMSveinsdóttir  SSigfússon  ASkaftadóttir  IJónasson  JGAgnarsson  BA Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2. Clin Exp Immunol 1999;117 (2) 252- 260
PubMed Link to Article
Renier  GIfrah  NChevailler  ASaint-Andre  JPBoasson  MHurez  D Four brothers with Waldenstrom's macroglobulinemia. Cancer 1989;64 (7) 1554- 1559
PubMed Link to Article
Treon  SPHunter  ZRAggarwal  A  et al.  Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006;17 (3) 488- 494
PubMed Link to Article
McMaster  MLGoldin  LRBai  Y  et al.  Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet 2006;79 (4) 695- 701
PubMed Link to Article
Aoki  HTakishita  MKosaka  MSaito  S Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenström's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood 1995;85 (7) 1913- 1919
PubMed
Wagner  SDMartinelli  VLuzzatto  L Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood 1994;83 (12) 3647- 3653
PubMed
Giordano  TPHenderson  LLandgren  O  et al.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297 (18) 2010- 2017
PubMed Link to Article
Boren  EGershwin  ME Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev 2004;3 (5) 401- 406
PubMed Link to Article
Coussens  LMWerb  Z Inflammation and cancer. Nature 2002;420 (6917) 860- 867
PubMed Link to Article
Landgren  OEngels  EAPfeiffer  RM  et al.  Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006;98 (18) 1321- 1330
PubMed Link to Article
Mellemkjaer  LPfeiffer  RMEngels  EA  et al.  Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum 2008;58 (3) 657- 666
PubMed Link to Article
Zintzaras  EVoulgarelis  MMoutsopoulos  HM The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165 (20) 2337- 2344
PubMed Link to Article
Linet  MSHumphrey  RLMehl  ES  et al.  A case-control and family study of Waldenstrom's macroglobulinemia. Leukemia 1993;7 (9) 1363- 1369
PubMed
Richardson  CWaldrop  J Veterans: 2000 Census 2000 Brief.  Washington, DC US Census Bureau2003;
Breslow  NEDay  NE Statistical Methods in Cancer Research, Volume II: The Design and Analysis of Cohort Studies.  Lyon, France International Agency for Research on Cancer1987;Scientific Publication No. 82:1-406
Theander  EHenriksson  GLjungberg  OMandl  TManthorpe  RJacobsson  LT Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65 (6) 796- 803
PubMed Link to Article
Alexander  DDMink  PJAdami  HO  et al.  The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007;120 ((suppl 12)) 1- 39
PubMed Link to Article
Walker  DH Rickettsiae and rickettsial infections: the current state of knowledge. Clin Infect Dis 2007;45 ((suppl 1)) S39- S44
PubMed Link to Article
Hutchings  APurcell  WMBenfield  MR Peripheral blood antigen-presenting cells from African-Americans exhibit increased CD80 and CD86 expression. Clin Exp Immunol 1999;118 (2) 247- 252
PubMed Link to Article
Kerman  RHKimball  PMVan Buren  CTLewis  RMKahan  BD Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation 1991;51 (2) 338- 342
PubMed Link to Article
Chen  QYJackson  NVargas  A  et al.  Identification of three genomic haplotypes 5′ to the human CD1D gene and their distribution in four ethnic groups. Tissue Antigens 2003;62 (5) 442- 448
PubMed Link to Article
Baldini  LGoldaniga  MGuffanti  A  et al.  Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005;23 (21) 4662- 4668
PubMed Link to Article
Lee  RRose  MSHarmer  CL Vinblastine-loaded platelets: their effect in a patient with immune thrombocytopenia associated with Waldenstrom's macroglobulinaemia. Clin Lab Haematol 1982;4 (1) 61- 65
PubMed Link to Article
Owen  RGLubenko  ASavage  JParapia  LAJack  ASMorgan  GJ Autoimmune thrombocytopenia in Waldenstrom's macroglobulinemia. Am J Hematol 2001;66 (2) 116- 119
PubMed Link to Article
Engels  EA Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16 (3) 401- 404
PubMed Link to Article
Fisher  SGFisher  RI The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications. Curr Opin Oncol 2006;18 (5) 417- 424
PubMed Link to Article
Percy  CVan Holten  VMuir  C International Classification of Diseases for Oncology. 2nd ed. Geneva, Switzerland World Health Organization1990;
Smedby  KEBaecklund  EAskling  J Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15 (11) 2069- 2077
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure.

Forest plots of the rate ratios (RRs) for specific conditions and subsequent Waldenström macroglobulinemia in black and white patients. The likelihood ratio test (LRT) provides a formal evaluation of the difference in RRs by race. Error bars indicate confidence intervals. All analyses were adjusted for age, calendar time, race, latency, and number of hospital visits.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1. Characteristics of the Study Cohort (US Veterans Affairs): White and Black Male Veterans With at Least 1 Hospital Admission Between July 1, 1969, and September 30, 1996, and Followed Up for More Than 1 Year
Table Graphic Jump LocationTable 2. Risk of Waldenström Macroglobulinemia (WM) in Relation to Previous Personal History of Selected Autoimmune Diseasesa
Table Graphic Jump LocationTable 3. Risk of Waldenström Macroglobulinemia (WM) in Relation to Previous Personal History of Selected Infectious Diseasesa
Table Graphic Jump LocationTable 4. Selected Infectious Conditions in Black and White Patients With and Without Waldenström Macroglobulinemia (WM)

References

Berger  FIsaacson  PGPiris  MA  et al.  Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Jaffe  ESHarris  NLStein  HVardiman  JW World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press2001;132- 134
Owen  RGTreon  SPAl Katib  A  et al.  Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003;30 (2) 110- 115
PubMed Link to Article
Fonseca  RHayman  S Waldenström macroglobulinaemia. Br J Haematol 2007;138 (6) 700- 720
PubMed Link to Article
Vijay  AGertz  MA Waldenström macroglobulinemia. Blood 2007;109 (12) 5096- 5103
PubMed Link to Article
Groves  FDTravis  LBDevesa  SSRies  LAFraumeni  JF  Jr Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 1998;82 (6) 1078- 1081
PubMed Link to Article
Morton  LMWang  SSDevesa  SSHartge  PWeisenburger  DDLinet  MS Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107 (1) 265- 276
PubMed Link to Article
Kyle  RATherneau  TMRajkumar  SV  et al.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102 (10) 3759- 3764
PubMed Link to Article
Kyle  RARajkumar  SVTherneau  TMLarson  DRPlevak  MFMelton  LJ  III Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance. Clin Lymphoma 2005;5 (4) 257- 260
PubMed Link to Article
Blattner  WAGarber  JEMann  DL  et al.  Waldenström's macroglobulinemia and autoimmune disease in a family. Ann Intern Med 1980;93 (6) 830- 832
PubMed Link to Article
Brown  AKElves  MWGunson  HHPell-Ilderton  R Waldenströms macroglobulinaemia: a family study. Acta Haematol 1967;38 (3) 184- 192
PubMed Link to Article
Elves  MWBrown  AK Cytogenetic studies in a family with Waldenström's macroglobulinaemia. J Med Genet 1968;5 (2) 118- 122
PubMed Link to Article
Gétaz  EPStaples  WG Familial Waldenström's macroglobulinaemia: a case report. S Afr Med J 1977;51 (24) 891- 892
PubMed
McMaster  MLGiambarresi  TVasquez  LGoldstein  AMTucker  MA Cytogenetics of familial Waldenstrom's macroglobulinemia: in pursuit of an understanding of genetic predisposition. Clin Lymphoma 2005;5 (4) 230- 234
PubMed Link to Article
Ogmundsdóttir  HMSveinsdóttir  SSigfússon  ASkaftadóttir  IJónasson  JGAgnarsson  BA Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2. Clin Exp Immunol 1999;117 (2) 252- 260
PubMed Link to Article
Renier  GIfrah  NChevailler  ASaint-Andre  JPBoasson  MHurez  D Four brothers with Waldenstrom's macroglobulinemia. Cancer 1989;64 (7) 1554- 1559
PubMed Link to Article
Treon  SPHunter  ZRAggarwal  A  et al.  Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006;17 (3) 488- 494
PubMed Link to Article
McMaster  MLGoldin  LRBai  Y  et al.  Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet 2006;79 (4) 695- 701
PubMed Link to Article
Aoki  HTakishita  MKosaka  MSaito  S Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenström's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood 1995;85 (7) 1913- 1919
PubMed
Wagner  SDMartinelli  VLuzzatto  L Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood 1994;83 (12) 3647- 3653
PubMed
Giordano  TPHenderson  LLandgren  O  et al.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297 (18) 2010- 2017
PubMed Link to Article
Boren  EGershwin  ME Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev 2004;3 (5) 401- 406
PubMed Link to Article
Coussens  LMWerb  Z Inflammation and cancer. Nature 2002;420 (6917) 860- 867
PubMed Link to Article
Landgren  OEngels  EAPfeiffer  RM  et al.  Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006;98 (18) 1321- 1330
PubMed Link to Article
Mellemkjaer  LPfeiffer  RMEngels  EA  et al.  Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum 2008;58 (3) 657- 666
PubMed Link to Article
Zintzaras  EVoulgarelis  MMoutsopoulos  HM The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165 (20) 2337- 2344
PubMed Link to Article
Linet  MSHumphrey  RLMehl  ES  et al.  A case-control and family study of Waldenstrom's macroglobulinemia. Leukemia 1993;7 (9) 1363- 1369
PubMed
Richardson  CWaldrop  J Veterans: 2000 Census 2000 Brief.  Washington, DC US Census Bureau2003;
Breslow  NEDay  NE Statistical Methods in Cancer Research, Volume II: The Design and Analysis of Cohort Studies.  Lyon, France International Agency for Research on Cancer1987;Scientific Publication No. 82:1-406
Theander  EHenriksson  GLjungberg  OMandl  TManthorpe  RJacobsson  LT Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65 (6) 796- 803
PubMed Link to Article
Alexander  DDMink  PJAdami  HO  et al.  The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007;120 ((suppl 12)) 1- 39
PubMed Link to Article
Walker  DH Rickettsiae and rickettsial infections: the current state of knowledge. Clin Infect Dis 2007;45 ((suppl 1)) S39- S44
PubMed Link to Article
Hutchings  APurcell  WMBenfield  MR Peripheral blood antigen-presenting cells from African-Americans exhibit increased CD80 and CD86 expression. Clin Exp Immunol 1999;118 (2) 247- 252
PubMed Link to Article
Kerman  RHKimball  PMVan Buren  CTLewis  RMKahan  BD Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation 1991;51 (2) 338- 342
PubMed Link to Article
Chen  QYJackson  NVargas  A  et al.  Identification of three genomic haplotypes 5′ to the human CD1D gene and their distribution in four ethnic groups. Tissue Antigens 2003;62 (5) 442- 448
PubMed Link to Article
Baldini  LGoldaniga  MGuffanti  A  et al.  Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005;23 (21) 4662- 4668
PubMed Link to Article
Lee  RRose  MSHarmer  CL Vinblastine-loaded platelets: their effect in a patient with immune thrombocytopenia associated with Waldenstrom's macroglobulinaemia. Clin Lab Haematol 1982;4 (1) 61- 65
PubMed Link to Article
Owen  RGLubenko  ASavage  JParapia  LAJack  ASMorgan  GJ Autoimmune thrombocytopenia in Waldenstrom's macroglobulinemia. Am J Hematol 2001;66 (2) 116- 119
PubMed Link to Article
Engels  EA Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007;16 (3) 401- 404
PubMed Link to Article
Fisher  SGFisher  RI The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications. Curr Opin Oncol 2006;18 (5) 417- 424
PubMed Link to Article
Percy  CVan Holten  VMuir  C International Classification of Diseases for Oncology. 2nd ed. Geneva, Switzerland World Health Organization1990;
Smedby  KEBaecklund  EAskling  J Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15 (11) 2069- 2077
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 18

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Autoimmune Manifestations in Patients With Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk Published online Jun 10, 2014.;